AllDocs -> cancers

ORIGINAL ARTICLE Ifosfamide Containing Regimen for Non-Small Cell Lung Cancer D. Behera, A.N. Aggarwal, S.C. Sharma 1 , D. Gupta and S.K. Jindal Departments of Pulmonary Medicine and Radiation Oncology 1 , Postgraduate Institute of Medical Education and Research, Chandigarh, India ABSTRACT Background. Combination chemotherapy has been demonstrated as one of the best active regimens in patients with non-small cell lung cancer (NSCLC). Methods. A total of 206 patients with advanced unresectable NSCLC stage III B or stage IV were enrolled to receive combination chemotherapy with mitomycin, ifosfamide and cisplatin. About a third of them (n=63) did not continue therapy after the first course either because of toxicity, lack of affordability, or death. The remaining 143 patients (121 males) received two or more cycles ...

FOREWORD by Finbarr O’Connell Lung cancer is the leading cause of cancer mortality in Ireland causing approximately 20% of all cancer deaths. Incidence in Irish men has fallen slightly in recent years and is below the EU average, but in Irish women is on the increase and is more than double the EU average. Lung cancer is likely to eclipse breast cancer as the leading cause of cancer mortality in Irish women in the near future and has already done so in some other countries. Unfortunately, despite the enormous burden of disease, the prevailing attitude to lung cancer , even among health care professionals, is one of pessimism, or at worst, absolute nihilism. This reflects poor overall survival rates, even in the minority of patients who present with apparent early-stage disease who are treated with intention to cure. Overall 5-year survival is less than 10% and despite advances ...

providing research and information services to the Scottish Parliament 1 Research Note 00/95 13 November 2000 LUNG CANCER AND ASBESTOS (MESOTHELIOMA) This note provides background information on S1M-1273, for debate on 16 November 2000, on compensation for mesothelioma sufferers. THE ISSUE S1M-1273 reads: 'that the Parliament notes the plight of shipyard workers and their families who were exposed to asbestos, became ill and have now contracted mesothelioma; expresses concern over the length of time their compensation cases are taking to reach conclusion and the use of so-called "blanket denials" by the defenders, and notes that this practice victimises and denies justice to these cancer sufferers.' 1 Sufferers have in mind to persuade the Parliament to precipitate a change in the law that will allow compensation claims to proceed more quickly ...

333 Bloc kley Hall 423 Guardian Drive Philadelphia, P A 1910 4-6 021 Non-Profit Org. U.S. P ost age PA ID Permit No. 25 63 Philadelphia, P A 1910 4 U NIVERSITY OF P ENNSYL VANIA S CHOOL OF M EDICINE Of fice of Continuing Medical Education Friday, May 14, 2004 Marriott Hotel 1201 Market Street, Philadelphia, Pennsylvania Sponsored by In Conjunction with The Department of Surgery, Section of General Thoracic Surgery and the Abramson Cancer Center at the University of Pennsylvania School of Medicine P r e s e n t Update in the Multidisciplinary Management of Early-stage Non-small Cell Lung Cancer A C M E - C E R T I F I E D C O U R S E Update in the Multidisciplinary ...

LUNG CANCER AWARENESS What is Lung Cancer ? Lung cancer is the uncontrolled growth of abnormal cells in one or both lungs. These abnormal cells repro- duce rapidly and cause damage to normal lung tissue. Lung cancer is now the most common form of cancer diagnosed in the United States and a major cause of death. Lung cancer accounts for 14 percent of all can- cers and 28 percent of all cancer -related deaths. Who is At Risk? Both men and women are at risk for lung cancer . You are more susceptible to lung cancer if you currently or formerly smoked. Exposure to certain types of chemicals and other substances can also make you suscepti- ble. Risk factors for lung cancer include: • Cigarette smoking • Cigars and pipes • A personal history of lung cancer • Exposure to certain industrial substances, such ...

-more- LUNG CANCER 101: DISEASE OVERVIEW The Condition Lung cancer is the uncontrolled growth of abnormal cells in one or both of the lungs. While normal lung tissue cells reproduce and develop into healthy lungs, these abnormal cells reproduce rapidly and never grow into normal lungs. Lumps of cancer cells (tumors) then form and disrupt the lung , making it difficult for the lung to function properly. More than 87 percent of lung cancers are smoking related. However, not all smokers develop lung cancer . Smoking cessation reduces an individual’s risk significantly, although former smokers remain at greater risk for lung cancer compared to people who never smoked. Exposure to other carcinogens such as asbestos and radon gas also increase an individual’s risk, especially when combined with cigarette or cigar smoking. Types The two main ...

lung cancer BRITISH THORACIC SOCIETY LUNG CANCER WORKING PARTY CONSENSUS STATEMENT ON SPECIALISED DIAGNOSTIC & THERAPEUTIC BRONCHOSCOPY Introduction: Specialised bronchoscopic techniques are available for diagnosis and for treatment of endobronchial disease. Principal treatment modalities are de-bulking techniques (electrocautery; forceps removal; laser; cryotherapy), photodynamic therapy, stenting, and brachytherapy. These modalities can be used alone or in combination to attempt cure or for symptom palliation, and can be combined with external beam radiotherapy for cancer , or prior to definitive surgery. Fluorescence Bronchoscopy (FB): Examples of the systems in use are laser imaging fluorescence endoscopy (LIFE); the Stortz D-light system; and the PENTAX SAFE 1000 system. Endobronchial ...

Let's Make Cancer History 1 8 8 8 9 3 9 - 3 3 3 3 I w w w. c a n c e r. c a Lung Cancer What you need to know Page 2 LUNG CANCER What you need to know Even though we hear about cancer almost every day, when you are diagnosed with cancer you may feel alone and afraid. You may also feel overwhelmed by all the information you are given and by the need to make so many decisions. This publication will give you and your family introductory information you need when you first learn that you have lung cancer . It will help you gain a sense of control and help you work with your healthcare team to choose the best treatments for you. Page 3 1 What is cancer ? Cancer is a disease that starts in our cells. Our ...

SMALL-CELL LUNG CANCER 107 CHAPTER 6 Small-cell lung cancer Bonnie S. Glisson, MD , Robert J. McKenna, Jr., MD , and Benjamin Movsas, MD Lung cancer has been the leading cause of cancer death in American men for years, and since 1988, it also has become the number-one cause of cancer death in American women. It is estimated that, in the year 2003, 171,900 new cases of lung cancer will be diagnosed, and 157,200 deaths due to this cancer will occur. Lung cancer appears to develop from a stem cell that can differentiate along multiple lines. Although it is not uncommon to find multiple cell types within a single lung tumor, one type usually predominates. Based on therapeutic ap- proach, there are two major subdivisions of lung cancer : small-cell carcinoma (SCLC), for which chemotherapy ...

Lung Cancer Management Study Day Aim To enable participants to have a general understanding of lung cancer epidemiology, diagnosis and treatment, including the social and psychosocial management. Learning Outcomes By the end of the day course participants will have: • An understanding of the incidence, risks and trends of lung cancer disease • A basic understanding of the clinical manifestations, tumour types and diagnostic methods used in lung cancer disease • Raised awareness of surgical procedures used in the management of lung cancer • A basic understanding of chemotherapy and radiotherapy in the treatment of lung cancer • Gained insight into the lung cancer issues arising through client personal experience . • An improved understanding of the manifestation, identification ...

Philadelphia, PA www.fccc.edu ? FACULTY ? Melvyn Goldberg, MD Vice Chairman, Surgical Oncology Chief, Thoracic Surgical Oncology ? Fox Chase Cancer Center Corey J. Langer, MD, FACP Medical Director, Thoracic Medical Oncology ? Fox Chase Cancer Center Benjamin Movsas, MD Vice Chairman, Radiation Oncology ? Fox Chase Cancer Center Michael Unger, MD, FACP, FCCP Director, Pulmonary Cancer Detection and Prevention Program Director, Pulmonary Endoscopy and High-Risk Lung Cancer Program ? Fox Chase Cancer Center STATEMENT OF THE FOX CHASE CANCER CENTER DISCLOSURE POLICY It is the policy of Fox Chase Cancer Center to insure that all sponsored continuing medical education activities are independently designed and produced, relative ...

R A D I A T I O N T H E R A P Y f o r LUNG CANCER Facts to Help Patients Understand Their Treatment ABOUT ASTRO The American Society for Therapeutic Radiology and Oncology is the largest radiation oncology society in the world. ASTRO's mission is to advance radiation oncology by promoting excellence in patient care, supporting research and distributing research results. LEARNING ABOUT CLINICAL TRIALS The radiation oncology team is always looking for new ways to treat and cure cancer through studies called clinical trials. Today's lung cancer radiation therapy treatments are the result of clinical trials completed in the past proving that radiation therapy kills cancer cells and is safe long term. For more information on clinical trials, please visit the following Web sites: National Cancer Institute ...

S pecial A rticle Management of elderly patients with lung cancer K.N. Syrigos 1 , G. Dionelis 2 ABSTRACT. The majority of patients with lung cancer (LC) are elderly patients, since 60% of the newly diagnosed patients with LC are >65 years old and 30% are >70 years old. It is common for elderly patients to suffer from a variety of chronic diseases and hence receive multiple drug treatments, which combined with their particular psychosocial and financial situation makes the process of diagnosis, staging and treatment of the disease difficult; there- fore, it is necessary to employ an individualized approach. We thor- oughly reviewed the differences between elderly and younger pa- tients with lung cancer and pinpoint the need for an individual- ized approach to the management of elderly patients with lung ...

MDACC Suspicion of Lung Cancer Clinical Presentation "Unresolved pneumonia" of 1 mo with abnormal CXR or Asymptomatic with abnormal CXR Hemoptysis Cough or Dyspnea CT of chest CXR and ENT exam CXR Positive for lung mass Bronchoscopy (with cytology and biopsy) Biopsy (FNA or bronchoscopy) *Low risk: nonsmoker; no risk factors for cancer . High risk: smoking history of 10 pack-years; any previous malignancy; asbestos exposure; or exposure to other known carcinogen. High risk* Low risk* Negative or low suspicion of neoplasm Negative for malignancy (V1.0 - 5/00) Treat other disease as indicated or Follow-up visit every 3 months Positive for malignancy Positive for lung mass Mass larger at observation? Yes ...

MDACC Small-Cell Lung Cancer Page 1 of 2 DIAGNOSIS INITIAL EVALUATION STAGE FURTHER WORKUP INITIAL TREATMENT If available, clinical trials should be offered as treatment options to eligible patients. Cisplatin and etoposide for 4 cycles Resection Mediastinoscopy Negative Positive Bronchoscopy or cytology via FNA History and physical Pathology review CBC, differential, platelets, Na, K, glucose, creatinine, total bilirubin, alka- line phosphatase, LDH, SGPT, Ca CT of chest and upper abdomen CXR ECG if history of heart disease Limited stage CT of brain Bone scan Bone marrow aspiration and biopsy if LDH elevated or abnormal CBC Thoracentesis if pleural effusion *See note below Solitary pulmonary ...

Non-Small Cell Lung Cancer Introduction The lungs are two spongy organs surrounded by a thin moist membrane called the pleura . Each lung is composed of smooth, shiny lobes: the right lung has three lobes and the left has two. About 90% of the lung is filled with air; only 10% is solid tissue. Air is carried from the trachea (the windpipe) into the lung through flexible airways called bronchi . • Like the branches of a tree, bronchi divide successively into over a million smaller airways called bronchioles . • The bronchioles lead to grape-like clusters of microscopic sacs called alveoli . • In each adult lung , there are about 300 million of these tiny alveoli, which are composed of a thin membrane through which oxygen and carbon dioxide pass to and from capillaries . • Capillaries, the smallest of our blood vessels, carry ...

EGAM 2004 EORTC LUNG CANCER GROUP PROGRAM 22.4.04 14.00 Welcome Minutes New treasurer (van Meerbeeck) Election for chair of chemotherapy subgroup (van Meerbeeck) New members, membership status, report of Quality Assurance Subcommittee (Ardizzoni) Calendar , publications/abstracts (Price) Finances (Biesma/van Meerbeeck) 1415 Closed trials 08941 Surgery vs RT in chemoresponsive patients with pN2 NSCLC ( van Meerbeeck- van Schil) 08971b Phase III study of adjuvant vaccination in LD SCLC (Giaccone) 08972 Sequential vs concomitant CT-RT in NSCLC (Belderbos) 08983 Phase III study of Chemotherapy in mesothelioma (van Meerbeeck) 1430 Open trials 22993/08993 PCI in ED SCLC (Slotman) 22003/08004 PCI in LD SCLC (Senan) 08012 Neoadjuvant CT in operable NSCLC (van Meerbeeck) 08013 Neoadjuvant ...

The 1st WJTOG INTERNATIONAL LUNG CANCER SYMPOSIUM PROGRAM Preoperative and Postoperative Adjuvant Therapy In Early Stage NSCLC Combined Modality in Locally Advanced NSCLC Treatment for Advanced/Metastatic NSCLC Molecular Targeted Therapy in NSCLC Treatment for the elderly/PS2 NSCLC Information : WJTOG 377-2 Ohno-higashi,Osakasayama City,Osaka 589-8511, Japan Tel 81-72-360-3123 Fax 81-72-360-2286 E-mail: info@wjtog.or.jp Secretary of the Symposium : Tomomi Fukuda Tel 81-6-6232-0433 Fax 81-6-6232-2797 E-mail: t-fukuda@sunpla-mcv.com Clinical Trials on Non-Small Cell Lung Cancer in USA, Europe and Japan Challenge for Lung Cancer

Lung Cancer Mortality Rates* Marion County 1988-1998 Source: Marion County Health Department *Rates are per 100,000 and are age-adjusted to the 1970 US standard population 0 20 40 60 80 100 120 Rate per 100,000 Population Total Male Female Total 71.9 71.7 75 67.3 65.9 65.2 69.8 64.4 63.2 65 69.4 71.3 61.2 Male 113.7 112.1 112 102.9 94.6 96.6 110.8 84.2 91.1 85.8 93.5 98.9 81.6 Female 44.2 44.9 48.7 43.3 46 44.5 41 51.1 42.9 51.2 52 51.4 46.5 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 Page 2 Lung Cancer Mortality Rates* Marion County 1988-1998 ...

Mesothelioma Lung Cancer Symptoms Lung cancer symptoms are rarely felt until the disease has developed into an advanced stage. Even when symptoms are felt, people often tolerate them for some time before they seek medical assistance. For instance, it's easy to shrug off shortness of breath as being out of shape, or a chronic cough as a bad cold or allergies. More obvious symptoms, such as coughing up blood or dyspnea (difficulty breathing), may occur before medical advice is asked for. Common lung cancer symptoms include: q Constant chest pain, q Chronic cough that worsens over time, q Coughing up blood (hemoptysis), q Dyspnea (difficulty breathing), q Fatigue, q Lung infection (pneumonia, bronchitis), q Shortness of breath, q Swollen lymph nodes, ...

lung cancer Lung Cancer Jaclyn Lenz Theresa O’Neil Jennifer Marchese Ben Linsky Karen Gable Brian Bertges What is Lung Cancer ? Develops in the lining of bronchi Takes several years to develop Precancerous changes form first Precancerous changes progress to true cancer and cancer cells cause more blood vessels to form which nourish these cells to grow Cells continue to grow and can be detected by x-rays Cells from the cancer can spread to other parts of the body in process of metasasis Lung cancer is life-threatening because it can spread this way before it is detected Lung cancer usually begins in the bronchi of the lungs Types of Lung Cancer Two major types Small cell cancer ...

Last revised: 12/15/2003 University of Michigan Comprehensive Cancer Center Patient Education Document # 0004 Jan04 Ed. Online version: http://www. cancer .med.umich.edu/learn/percpathways.htm University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Lung Cancer The purpose of this information guide is to help newly diagnosed lung cancer patients and their families to find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center at the University of Michigan Comprehensive Cancer Center in room B1-361. Pamphlets Available free in the Patient Education Resource Center on level B-1 National ...

QUESTIONS & ANSWERS ABOUT LUNG CANCER Q: What are the early signs of lung cancer ? How would I know I have it? A: Some of the early warning signs of lung cancer are: • A cough that doesn’t go away • Chest pain • Hoarseness • Weight loss and loss of appetite • Bloody or rust-colored sputum • Shortness of breath • Fever without a known reason • Recurring infections such as bronchitis or pneumonia These symptoms can also come from other diseases, so seeing your health care provider is the only way to find out what may be causing these symptoms. Q: How is lung cancer diagnosed? A: Your doctor may do one or more of ...

WHERE TO FIND MORE INFORMATION ON LUNG CANCER The National Cancer Institute, International Cancer Information Center Bldg. 82, Rm 123 Bethesda, MD 20892 The American Cancer Society The American Lung Association 1840 Broadway New York, NY 10019 The National Jewish Medical & Research Center/ National Asthma Center 1400 Jackson St. Denver, CO 80206-2761 Your Health Care Provider The National Cancer Institute (NCI) is part of the Federal Government. NCI coordinates the government's cancer research program. It is the largest of the 17 biomedical research institutes and centers at the National Institutes of Health (NIH). It is located just outside Washington, ...

Research Updates January 2004 Alliance for Lung Cancer Advocacy, Support, and Education 500 W. 8 th Street, Suite 240, Vancouver, WA 98660 Lung Cancer Hotline: 800-298-2436 (US only) www.alcase.org 1 Trastuzumab (Herceptin ® ) Adds Little to Effects of Standard Chemotherapy for Advanced NSCLC Researchers from Germany have announced results from a phase II clinical trial that studied the effects of trastuzumab (Herceptin ® ) in combination with standard chemotherapy for the treatment of advanced NSCLC. The study of 100 people found the addition of trastuzumab led to no significant improvements over chemotherapy alone. 1 While the results were disappointing, researchers stated there may still be a role for trastuzumab (a monoclonal antibody) among people whose lung cancer ...

Page 1 Gefitinib for NSCLC Protocol TECHNOLOGY ASSESSMENT REPORT FOR THE HTA PROGRAMME FINAL VERSION: 27 January 2004 Title: Gefitinib for non-small cell lung cancer A. Details of appraisal group Correspondence to: Rumona Dickson, Ms Director, LRiG Liverpool Reviews and Implementation Group (LRiG) New Medical School Ashton Street Liverpool, UK L69 3GE Tel: 0 151 794 5682/5067/5541 Fax: 0 151 794 5678 Email: R.Dickson@liv.ac.uk Details of other members of the appraisal group Boland A, Research Fellow, Health Economics Bagust A Senior Research Fellow, Health Economics Dodd S Research Assistant, Medical Statistics Dundar Y Research Fellow, Clinical Effectiveness Haycox A Senior Lecturer, Health Economics Hill RA Research ...

Current Abstracts on Lung Cancer in Women Author(s) Kiyohara-Chikako Email : chikako@phealth . med . kyushu-u . ac . jp , Wakai-Kenji , Mikami-Haruo , Sido-Koichi , Ando-Masahiko , Ohno-Yoshiyuki . Title Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer : A case-control study in Japanese nonsmoking women. Source International Journal of Cancer , 20 October, 2003, vol. 107, no. 1, p. 139-144, ISSN: 0020-7136. Author affiliation Kiyohara-Chikako, Department of Preventive Medicine, Division of Social Medicine, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi- Ku, Fukuoka, 812-8582, Japan. Abstract Genetic backgrounds may modify the association of environmental tobacco smoke (ETS) with lung cancer risk. ...

W. Michael Alberts, MD, MBA, FCCP Associate Center Director for Clinical Affairs, H. Lee Moffitt Cancer Center and Research Insti- tute; Interim-Chair and Professor, Interdisciplinary Oncology, Uni- versity of South Florida College of Medicine, Tampa, FL Disclosure: Speaker’s Bureau: Bristol-Myers Squibb, AstraZeneca CONTRIBUTING FACULTY Gene L. Colice, MD, FCCP Director, Pulmonary, Critical Care and Respira- tory Services, Washington Hospital Center, Washington, DC Disclosure: No financial relationships with a commercial party to disclose. Corey J. Langer, MD Director, Thoracic and Head and Neck, Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA Disclosure: Grant/Research Support: Bristol-Myers Squibb, Pharmacia, Lilly, Schering-Plough Research Institute, Aventis, Amgen, Cell Therapeutics, Inc., OrthoBiotech, Celgene, ...

Harvard Center for cancer prevention Harvard school of public health 665 Huntington Avenue Boston, Ma 02115 | 617.432.0038 www.hsph.harvard.edu/ cancer | hccp@hsph.harvard.edu The Lungs The lungs are sponge-like organs that bring air in and out of the body through the trachea. The trachea divides into tubes called bronchi, which divide into bronchioles. Lung cancer usually starts in the lining of the bronchi. Lung Cancer Lung cancer occurs when cells in the airways to the lungs grow out of control. The cells clump together and form a malignant (cancerous) tumor. Burden of Disease • Lung cancer is the leading cause of cancer death among men and women in the US, accounting for approximately 167,000 deaths each year (99,000 deaths in men and 68,000 deaths in women). • Because of cigarette smoking patterns over ...